ArticleBMC primary care2026
Barriers and facilitators to practitioner prescribing and patient adoption of anti-inflammatory maintenance and reliever therapy (MART) for adult asthma: a qualitative study.
Article in BMC primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsthma was traditionally treated with separate corticosteroid (ICS) containing ('preventer') and short-acting beta-agonist (SABA; 'reliever') inhalers. But overuse of SABA-reliever inhalers is common and associated with poor outcomes. Clinical guidelines increasingly recommend using combined ICS and formoterol (ICS-formoterol) as an anti-inflammatory reliever. While ICS-formoterol use as a reliever only, without maintenance doses, has only recently been licenced in the United Kingdom; use as both preventer and reliever (Maintenance and Reliever Therapy; MART) has been recommended for many years. Despite the evidenced benefits of this approach, MART uptake in the UK has been low.
methodsWe studied the barriers and facilitators to primary care practitioners' prescribing and adult asthma patients' adoption of MART. We recruited practitioners and patients from a network of general practices that had participated in the SENTINEL programme to address SABA over-use and support MART adoption. Semi-structured, theoretically underpinned interviews were conducted with both groups. Data analysis involved deductive coding to the theoretical domains framework (a comprehensive framework including all potential determinants of practitioner and health behaviours) followed by inductive coding within domains.
resultsFourteen themes were identified, with novel findings. Facilitators were practitioner knowledge and skills, and practice prescribing and appointment systems. Practitioner barriers mostly related to available resources, changes to treatment following emergency hospital presentations, and managing patient barriers to MART adoption and maintenance. Patient barriers included: psychological dependence on SABA-relievers and associated fear of discontinuation lack of understanding of the rationale for change to MART; and reluctance to change caused by concerns about difficulty getting an appointment if their asthma control deteriorated. Some practitioner barriers reported by previous studies (e.g., guideline knowledge and asthma management skills) were identified as facilitators in our study, potentially due to SENTINEL Programme participation.
conclusionsThe Global Initiative for Asthma (GINA) endorse ICS-formoterol as the preferred reliever in asthma, making it vital to understand barriers and facilitators to clinician and patient adoption in practice. We identified unique and previously unreported barriers and facilitators for both groups with potential to inform strategies to support practitioner and patient concordance with anti-inflammatory reliever-based asthma treatment and implementation of evidence-based, guideline-recommended care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.